Dian Diagnostics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dian Diagnostics - overview
Established
1996
Location
Hangzhou, Zhejiang, China
Primary Industry
Healthcare
About
Based in Hangzhou, China, and founded in 1996, Dian Diagnostics Group Co. , Ltd. provides medical diagnostic services and products for the healthcare sector. The company was formerly known as Zhejiang D.
A. Diagnostics Co. , Ltd. In July 2011, the company completed an IPO on the Shenzhen Stock Exchange under the ticker symbol "300244.
" The company works with over 22,000 medical institutions to provide diagnostic service outsourcing, diagnostic technology research and development, and diagnostic product manufacturing. It offers more than 4,500 testing items and processes over 100 million samples annually. The company's business ecosystem also includes cold chain logistics, judicial appraisal, health management, and big data and artificial intelligence solutions. The company generates revenue from B2B contracts by offering third-party medical diagnostic services, laboratory outsourcing, and the sale of diagnostic equipment and products to medical facilities.
Current Investors
SB China Venture Capital, Shanghai Fosun Pharmaceutical (Group)
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
www.dazd.cn/
Verticals
Artificial Intelligence, Big Data, HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Dian Diagnostics - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 482,474,271.5 | 706,418,723.5 | 1,015,474,436.7 | 1,335,100,144.2 | 1,857,529,073 | 3,823,115,273.4 | 5,003,413,431.1 | 6,966,178,185.5 | 8,451,347,300.9 | 10,647,504,594.8 | 13,082,613,200.2 | 20,282,469,258.3 | - | - | - |
| % Revenue Growth (YoY) | - | 46.4% | 43.7% | 31.5% | 39.1% | 105.8% | 30.9% | 39.2% | 21.3% | 26.0% | 22.9% | 55.0% | - | - | - |
| EBITDA (USD) | 54,626,930.5 | 85,365,229.4 | 134,488,771.2 | 183,257,460.2 | 269,884,059.4 | 529,667,846.3 | 859,031,653 | 1,123,537,058.2 | 1,287,701,416.1 | 1,881,880,560.2 | 2,179,502,917.9 | 3,412,817,019.9 | - | - | - |
| Operating Income (USD) | 42,565,186.6 | 66,239,960.9 | 105,921,791.6 | 147,408,399.9 | 217,055,500.4 | 449,688,538.7 | 704,510,589.5 | 892,448,314.3 | 983,286,189.1 | 1,516,186,197.6 | 1,837,934,540.2 | 2,822,608,567.7 | - | - | - |
| Operating Margin | 8.8% | 9.4% | 10.4% | 11.0% | 11.7% | 11.8% | 14.1% | 12.8% | 11.6% | 14.2% | 14.0% | 13.9% | - | - | - |
| % EBITDA Margin | 11.3% | 12.1% | 13.2% | 13.7% | 14.5% | 13.9% | 17.2% | 16.1% | 15.2% | 17.7% | 16.7% | 16.8% | - | - | - |
| NET Income (USD) | 41,580,396.4 | 59,393,420.3 | 90,034,193 | 127,852,579 | 178,785,435.5 | 337,950,236.5 | 464,091,987.5 | 588,461,903.6 | 575,568,057.1 | 1,069,934,110.5 | 1,483,601,123.1 | 1,862,469,998 | - | - | - |
| % Net Margin | 8.6% | 8.4% | 8.9% | 9.6% | 9.6% | 8.8% | 9.3% | 8.4% | 6.8% | 10.0% | 11.3% | 9.2% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.